viewShield Therapeutics PLC

Shield Therapeutics makes a profit and is 'cash positive' during first-half of the year

Shield Therapeutics PLC's (LON:STX), Tim Watts talks to Proactive London about their latest interim results for the six months ended June 30, 2020 which resulted in a profit.

Watts looks back to the $11.4m deal signed in January with China's ASK Pharm and the progress made in agreeing the development plan with the Chinese regulatory authorities as the company looks ahead to expand the territories in which Ferracru® is marketed.

He also notes how Norgine grew net sales of Ferracru® in Europe by 50% and the first half sales in 2020 have matched the sales for the whole of 2019.

Quick facts: Shield Therapeutics PLC

Price: 143 GBX

Market: LSE
Market Cap: £167.58 m


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Shield Therapeutics PLC named herein, including the promotion by the Company of Shield Therapeutics PLC in any Content on the Site, the Company...



Shield Therapeutics: Analysis of data from AEGIS-H2H is strongly supportive...

Proactive Research analyst Emma Ulker says further conclusions from Shield Therapeutics' (LON:STX) analysis of data from the AEGIS-H2H study are strongly supportive of ongoing discussions for the global commercialisation, pricing and reimbursement of Feraccru. She adds that with the analysis...

on 10/8/20

2 min read